Sunitinib Malate for the Treatment of Pancreatic Neuroendocrine Tumors

20112,525 citationsJournal Article

Authors

Éric Raymond · Hôpital Beaujon

Laëtitia Dahan

Jean‐Luc Raoul · Centre Eugène Marquis

Yung‐Jue Bang · Seoul National University Hospital

Ivan Borbath · Cliniques Universitaires Saint-Luc

Catherine Lombard‐Bohas · Hospices Civils de Lyon

Juan W. Valle · National Health Service

Abstract

Continuous daily administration of sunitinib at a dose of 37.5 mg improved progression-free survival, overall survival, and the objective response rate as compared with placebo among patients with advanced pancreatic neuroendocrine tumors. (Funded by Pfizer; ClinicalTrials.gov number, NCT00428597.).

Topics & Keywords

Neuroendocrine Tumor Research Advances Lung Cancer Research Studies Pancreatic and Hepatic Oncology Research

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: New England Journal of Medicine

Volume 364, Issue 6, pp. 501-513

DOI: 10.1056/nejmoa1003825

Field-Weighted Citation Impact: 152.29